Metabolome, as a sum of small molecules which reflects, both of genetic and environmental factors affecting human's health at a given time, seems to be a perfect tool for describing physiological or pathological processes and in the result identifying biomarkers or introducing personalized treatment approach. To reach such important goals, a reliable and reproducible analytical methods are needed [1]. Until today, many different techniques were employed to investigate human metabolome such as separation techniques (gas chromatography (GC), liquid chromatography (LC)) coupled to mass spectrometry (MS) or nuclear magnetic resonance (NMR) spectroscopy [2]. None of these techniques seems to be perfect for reliable analysis of the whole metabolome yet. Thus, researchers' efforts are focused on developing tools which might enable identifying and quantifying as many ABSTRACT Introduction. Recent instrumentation and software advancement enabled to develop new, high-throughput targeted metabolomics methods for in-depth exploration of metabolome in a quantitative manner. Material and Methods. The presented targeted metabolomics approach allows to analyze both of serum and CSF in the same way, with identical sample preparation procedures. The analyses were carried out using high-performance liquid chromatography system coupled to triple quadrupole tandem mass spectrometer with electrospray ion source (LC-ESI-QqQ-MS/MS).
Introduction
Metabolome, as a sum of small molecules which reflects, both of genetic and environmental factors affecting human's health at a given time, seems to be a perfect tool for describing physiological or pathological processes and in the result identifying biomarkers or introducing personalized treatment approach. To reach such important goals, a reliable and reproducible analytical methods are needed [1] . Until today, many different techniques were employed to investigate human metabolome such as separation techniques (gas chromatography (GC), liquid chromatography (LC)) coupled to mass spectrometry (MS) or nuclear magnetic resonance (NMR) spectroscopy [2] . None of these techniques seems to be perfect for reliable analysis of the whole metabolome yet. Thus, researchers' efforts are focused on developing tools which might enable identifying and quantifying as many metabolites as possible. Until recently, untargeted metabolomics approach was prevailing in discovery-based investigations, but today due to instrumentation and software development we can apply high-throughput targeted metabolomics methods [3] to explore metabolome in a quantitative manner [4] . That approach allows the researchers to skip time consuming step of identifi cation of relevant metabolites -characteristic for untargeted approach, and to focus on data interpretation taking into account clinical needs (e.g. data comparability to reference ranges). The aim of the study was the application of targeted metabolomics method allowing to analyze wide spectrum of metabolites from fi ve different chemical classes of compounds in serum and cerebrospinal fluid (CSF) from human subjects, in the same way.
Materials and Methods
Quantitative metabolomics of CSF and serum covers wide spectrum of analytes form different groups of compounds, including: 40 acylcarnitines, 21 biogenic amines, 21 amino acids, 90 glycerophospholipids (14 lysophosphatidylcholines and 76 phosphatidylcholines), 15 sphingolipids and sum of hexoses. It yields the total of 188 metabolites quantifi ed simultaneously (Figure 1) . The assays were performed using AbsoluteIDQ p180 kit (Biocrates Life Sciences AG, Innsbruck, Austria) according to standard operation procedures. The methodology is based on 2-layers, 96-deepwell plate supplied by manufacturer, with selected internal standards partially integrated with fi lter layer of the plate.
10 serum and 10 CSF samples were analyzed. All samples were collected from patients who has no diagnosed nervous system disorders. The research was performed in accordance with the Declaration of Helsinki. All study subjects gave written informed consent prior the sample collection. (Bioethics Committee of Poznan University of Medical Sciences -Decision no. 821/16 and 206/17). First step of analytical workflow was to add 10 μL of internal standards mixture containing rest of internal standards on the fi lter layer. Then phosphate buffered saline, seven calibration standards of different concentration and quality Figure 1 . List of all metabolites analyzed using Absolute IDQ p180 methodology in FIA-MS/MS mode and LC-MS/MS mode controls samples (QC) were put in the respective wells. 3 concentration levels (low, medium, high) of QC samples were analyzed. Biological samples were thawed in room temperature and pipetted on the appropriate spots in amount of 10 μL and 30 μL of serum and CSF, respectively. The plate was then dried under nitrogen flow for 30 minutes. During that time the derivatization agent was prepared by vortexing rigorously 300 μL of phenylisothiocyanate (PITC) with 5700 μL of mixture of pyridine and ethanol in water (1:1:1). After 30-minutes of drying, 50 μL of derivatization solution was put in each well. Covered plate was left for 20-minutes incubation at room-temperature. Next the second round of drying under nitrogen flow was performed for 60 minutes. Then 300 μL of extraction solvent containg 5 mM of ammonium acetate in methanol was pipetted to each well, after which covered plate was shaken at room temperature for 30 minutes using orbital plate shaker at 450rpm. Subsequently sample extracts were passed through the fi lter layer to the lower capture plate via nitrogen pressure. Finally sample extract was split into two analogous 96-well plates and diluted with 150 μL of water and 400 μL of FIA mobile phase for LC-MS/ MS analysis and FIA-MS/MS analysis, respectively. Each plate was sealed with silicone mat to reduce evaporation and placed in autosampler.
The LC run as well as FIA run were carried out using high-performance liquid chromatography system 1260 Infi nity (Agilent Technologies, Santa Clara, CA, USA) coupled to triple quadrupole tandem mass spectrometer 4000 QTRAP (Sciex, Framingham, MA, USA). Quantifi cation of amino acids and biogenic amines was preceded by chromatographic separation (LC-MS/MS part) using 0.2% solution of formic acid (phase A) and 0.2% formic acid in acetonitrile (phase B) at the flow rate 0.5 mL/min. Gradient elution was as follows: 0-0.5 min, 100% phase A; 0.5-5.5 min, linear to 5% phase A; 5.5-6.5 min holding at 5% phase A; followed by returning to 100% phase A (6.5-7.0 min); and fi nally 7.0-9.5 min, 100% phase A. The chromatography was carried out on an ZOR-BAX Eclipse XDB-C18 (3.0 x 100 mm, 3.5 μm) column (Agilent Technologies, Santa Clara, CA, USA), with a pre-column (C18, 4.0 x 3.0 mm) SecurityGuard (Phenomenex, Torrance, CA, USA). In turn, remaining metabolites were determined by injecting sample into mobile phase, at isocratic flow, directly to mass spectrometer (flow injection analysis, FIA-MS/MS). These compounds were analyzed by mass spectrometer only, bypassing the chromatographic column, according to different m/z ratios.
Data acquisition and quantifi cation were performed under control of Analyst 1.5.2 software (Sciex, Framingham, MA, USA). Sample management and data processing were carried out using MetIDQ version Boron software (Biocrates Life Sciences AG, Innsbruck, Austria). In the next step the raw data (obtained as chromatographic peaks) for QC samples and calibrators were manually reviewed and peak integrations were checked in order to validate the performance of both acquisition and quantitation methods of in-house MS-system. To confi rm the reliability of the results, the QC samples evaluation using software build-in tool (MetVAL module, Biocrates Life Sciences AG, Innsbruck, Austria) was performed. Afterwards the concentrations of metaboliteswere calculated (μM) using MetSTAT module (Biocrates Life Sciences AG, Innsbruck, Austria). The metabolites with 50% or more of missing data (concentration below limit of detection) were excluded. Then, the remaining missing data was replaced with half of minimal determined concentration for appropriate metabolite.
Results
Two different matrices: serum and cerebrospinal fluid from human subjects were analyzed using targeted metabolomics approach, according to manufacturer's operation procedures. Quality assessment of the data was passed by QC samples analyzed in LC-MS/MS analysis, as well as QC samples analyzed in FIA-MS/MS analysis (all tested metabolites concentration levels were within reference ranges), indicating satisfactory accuracy and the performance of the method. In subjects' sera 148 metabolites were determined, including: 14 acylcarnitines, 21 amino acids, 13 biogenic amines, 84 glycerophospholipids, 15 sphingolipids and sum of hexoses. Conversely, in CSF 57 metabolites were determined, and they were as follow: 1 acylcarnitine, 18 amino acids, 5 biogenic amines, 23 glycerophospholipids, 9 sphingolipids and sum of hexoses ( Table 1) . It corresponds to 78.72% (serum) and 30.32% (CSF) of the total of 188 metabolites possible to quantitate with applied methodology. The full list of determined metabolites is given in Table 2 . All possible amino acids and sphingolipids as well as sum of hexoses, were determined in human serum. In the remaining groups of compounds some metabolites were not observed in serum or they did not exceed limit of detection. Nevertheless, abovementioned targeted metabolomics approach enables determining 35.0% acylcarnitines, 61.90% biogenic amines and 93.33% glycerophospholipids amongst wider spectrum of compounds. In case of CSF the applied approach enables determining: sum of hexoses, 85.71% 367 P C a a C 3 4 : 3 1 2 . 4 2 6 4 . 0 7 6 5 . 5 4 0 1 7 . 7 0 0 ----P C a a C 3 4 : 4 1 . 6 2 4 0 . 6 7 3 0 . 7 2 2 2 . 8 9 0 ----P C a a C 3 6 : 0 3 . 8 8 0 1 . 7 3 3 1 . 9 5 0 6 . 0 . 6 7 7 1 . 7 6 0 ----P C a e C 3 6 : 1 7 . 9 9 2 1 . 6 9 8 5 . 5 9 0 1 0 . 7 0 0 ----P C a e C 3 6 : 2 1 1 . 5 7 6 3 . 1 7 8 6 . 3 4 0 1 8 . 0 0 0 ----PC ae C36:3 7.687 2.199 3.700 10.200 0.012 0.008 0.002 0.023 P C a e C 3 6 : 4 1 8 . 8 6 9 5 . 0 1 3 8 . 3 9 0 2 6 . 3 0 0 ----PC ae C36:5 18.060 8.069 10.600 32.000 0.057 0.050 0.014 0.151 P C a e C 3 8 : 0 1 . 9 9 3 0 . 4 8 6 1 . 3 5 0 2 . 8 6 0 ----P C a e C 3 8 : 1 0 . 9 6 7 0 . 4 4 9 0 . 4 3 7 1 . 8 3 0 ----P C a e C 3 8 : 2
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It is easily seen that the quantifi cation of 148 metabolites in serum and 57 in CSF has result in changes of contribution of particular groups of metabolites determined in both fluids compared to their contribution in the whole set of 188 metabolites provided by the applied methodology. Figure 2 presents metabolites in the spectrum of: 188 compounds evaluated in applied methodology ( Figure 2A) ; 148 metabolites determined in serum ( Figure 2B) ; 57 metabolites determined in CSF ( Figure 2C ). The change in numbers of determined acylcarnitines is the highest. Among 40 acylcarnitines possible to quantitate 14 was determined in serum and only 1 in CSF, which corresponds to 9% of metabolites of this group of compounds quantifi ed in serum and 2% of metabolites quantifi ed in CSF. Here we presented the results of successful implementation of method of the determination of low-molecular weight compounds in human serum and CSF. The assays were performed by using hyphenated mass spectrometric techniques: LC-MS/MS and FIA-MS/MS. This targeted strategy has emerged as a satisfactory compromise between wide spectrum of analyzed compounds (characteristic for untargeted approach) and highly selective and sensitive measurement of selected compounds (targeted approach; MRM mode). What is worth to emphasize, despite different composition of CSF and serum, presented method allows to analyze both matrices in the same way, with identical sample preparation procedures. During the whole analysis the only noteworthy difference between these matrices is an amount of sample pipetted onto the 96-well plate. It gives the invaluable tool for simultaneous analysis CSF and serum that might be crucial for central nervous system (CNS) disorders research. The better understanding of correlation between CSF and serum metabolome as well as the blood-brain barrier permeability for metabolites in different medical conditions could contribute to reducing the number of invasive diagnostic procedures such as lumbar puncture in the future [9] . The limitation of the study is limited number of analyzed samples resulting from invasiveness of CSF collection. That is why we recommend to analyze these data with respect to other metabolomics cohort studies.
Presented results from implementation of the method of evaluation of selected groups of metabolites resulted in obtaining the mean concentrations of panel of metabolites in serum and CSF, which gives a valuable information about metabolome of these matrices for other researchers focused directly on investigations of e.g. central nervous system disorders. This is crucial due to the fact of lacking wide-spectrum targeted metabolomics data of both serum and CSF from human subjects. And secondly, presented results are highly translatable and can be easily compared through the application of widely used methodology with confi rmed interlaboratory reproducibility [10] and validation according to European Medicine Agency Guideline [11] . To conclude, we successfully implemented targeted metabolomics method allowing to analyze both of serum and CSF in the same way, and we applied it to analyze serum and CSF from human subjects. Evaluation of 148 metabolites in serum and 57 metabolites in CSF gives a tool for searching for disturbances in metabolism and enables determination of the broad variety of compound classes and confi rms usefulness of described methodology for further studies on both serum and CSF metabolome.
